Key Dates

Related Announcements

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PAR-23-034 - NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)

PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

PAR-21-271 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)

PA-20-199 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

PA-20-205 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

PA-21-047 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)

PA-21-048 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

PA-21-050 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

PA-21-052 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

PAR-21-155 - Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)

PAR-22-180 - Maximizing Investigators' Research Award (R35 Clinical Trial Optional)

PA-22-176 - PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

PA-22-178 - PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

PAR-22-126 - Technology Development Research for Establishing Feasibility and Proof of Concepts (R21 - Clinical Trial Not Allowed)

PAR-22-127 - Focused Technology Research and Development (R01 Clinical Trial Not Allowed)

PAR-20-104 - Biomedical Technology Development and Dissemination Center (RM1 - Clinical Trial Not Allowed)

PAR-21-169 - Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)

PAR-21-173 - Support for Research Excellence - First Independent Research (SuRE-First) Award (R16 Clinical Trial Not Allowed)

Issued by

National Institute of General Medical Sciences (NIGMS)

National Library of Medicine (NLM)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Data Science Strategy (ODSS)

Purpose

The purpose of this Notice of Special Interest (NOSI) is to inform the scientific community of the interest of NIGMS, NLM, and ODSS in supporting efficiency optimization and cost reduction for Sequence Read Archive (SRA) data storage and utilization.

Research Objectives

The SRA, hosted by the National Center for Biotechnology Information (NCBI) at NLM, contains a broad collection of raw DNA and RNA sequence data and alignment information that continues to grow exponentially. SRA supports several scientific use cases, such as replication of a published study, data analysis to identify genetic variation, metagenomic profiling, expression analysis, and pathogen identification. Committed to store, preserve, and make the SRA available to the community, NIH recognizes the need to reduce the cost of SRA data storage and identify solutions for efficient SRA data storage, retrieval, and analysis. This NOSI encourages grant applications focused on efficiency optimization and cost reduction for SRA data storage and utilization. NIH is particularly interested in identifying efficient solutions for SRA data compression and representation while still meeting the needs of a range of use cases, including but not limited to:

• Assessment of current SRA data formats and proposed future refinements and utilization costs for scientific use cases
• Development of novel SRA data compression formats, methods, data representation strategies, and utility assessment for different use cases
• Development of tools that utilize current SRA compressed data formats to enable their use by or integration with existing bioinformatics tools
• Development of compressed and/or lower-cost SRA data formats to meet the needs of a range of use cases

Application and Submission Information

This NOSI applies to due dates on or after January 17, 2023 and subsequent application due dates through December 19, 2025. Submit applications for this NOSI using one of the following Funding Opportunity Announcements (FOAs) or any subsequent reissues through the expiration date of this Notice.

Applicants must select the IC and associated FOA to use for submission of an application in response to the NOSI. Applicants using NIH Parent announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those FOAs are acceptable and based on usual application-IC assignment practices.

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include NOT-GM-23-015 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries